All In Biotech

Drug Trial Radar · NCT03478982

Inpatient, Dose-Ranging Study of Staccato Alprazolam in Epilepsy With Predictable Seizure Pattern

A Double-Blind, Placebo-Controlled, Inpatient, Dose-Ranging Efficacy Study of Staccato Alprazolam (STAP-001) in Subjects With Epilepsy With a Predictable Seizure Pattern

Last checked: Nov 20, 2026Latest source record: Feb 3, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 156 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

156

Actual

Start

Mar 16, 2018

Primary completion

Dec 22, 2019

Study completion Jan 4, 2020

Sponsor

Lead sponsor
Engage Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Mar 27, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-center, double-blind, randomized, parallel group, dose-ranging study to investigate the efficacy and clinical usability of STAP-001 in adult (18 years of age and older) subjects with epilepsy with a predictable seizure pattern. These subjects have an established diagnosis of focal or generalized epilepsy with a documented history of predictable seizure episodes. This is an in-patient study. The subjects will be admitted to a Clinical Research Unit (CRU) or Epilepsy Monitoring Unit (EMU) for study participation. The duration of the stay in the in-patient unit will be 2-8 days. One seizure event per subject will be treated with study medication. The duration and timing of the seizure event and occurrence of subsequent seizures will be assessed by the Staff Caregiver(s)1 through clinical observation and confirmed with video electroencephalogram (EEG).

Conditions

  • Epilepsy

Interventions

  • Staccato AlprazolamDrug

    single dose for inhalation

  • PlacebosDrug

    single dose for inhalation

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants in Each Treatment Group Achieving Seizure Activity Cessation Within 2 Minutes and no Recurrent Seizure Within 2 HoursTime frame: 2 hours post-dosing on dosing day

Locations

67 sites in 3 countries. Site status is shown where the registry gives one.

  • UAB Hospital

    Birmingham, Alabama

  • University of Arizona

    Phoenix, Arizona

  • St. Joseph's Hospital and Medical Center - Barrow Neurological Institute

    Phoenix, Arizona

  • Clinical Trials Inc

    Little Rock, Arkansas

  • Rancho Research Institute Inc.

    Downey, California

  • UCLA

    Los Angeles, California

  • Hoag Hospital

    Newport Beach, California

  • Stanford Neuroscience Health Center

    Palo Alto, California

  • Havana Research Institute LLC.

    Pasadena, California

  • University of Colorado

    Aurora, Colorado

  • Yale University

    New Haven, Connecticut

  • VA Connecticut Healthcare System

    West Haven, Connecticut

  • Georgetown University Hospital

    Washington D.C., District of Columbia

  • GW Medical Faculty Associates

    Washington D.C., District of Columbia

  • NW FL Clinical Research Group LLC

    Gulf Breeze, Florida

  • University of Florida Health Science Center Jacksonville

    Jacksonville, Florida

  • Mayo Clinic Florida

    Jacksonville, Florida

  • Clinical Translational Research Site

    Miami, Florida

  • Advanced Pharma Cr, LLC

    Miami, Florida

  • Nicklaus Children's Hospital

    Miami, Florida

  • AdventHealth Orlando

    Orlando, Florida

  • Research Institute of Orlando, LLC

    Orlando, Florida

  • NeuroMedical Research Institute

    Panama City, Florida

  • Center for Rare Neurological Diseases

    Norcross, Georgia

  • Clinical Research Institute

    Stockbridge, Georgia

  • Hawaii Pacific Neuroscience

    Honolulu, Hawaii

  • Northwestern Memorial Hospital

    Chicago, Illinois

  • Rush University Medical Center

    Chicago, Illinois

  • University of Kansas Medical Center

    Kansas City, Kansas

  • Ochsner Health System

    New Orleans, Louisiana

  • Maine Medical Center

    Scarborough, Maine

  • Mid-Atlantic Epilepsy And Sleep Center, LLC

    Bethesda, Maryland

  • Harvard Medical School - Brigham and Women's Hospital

    Boston, Massachusetts

  • University of Michigan

    Ann Arbor, Michigan

  • Bronson Methodist Hospital

    Kalamazoo, Michigan

  • SRI International

    West Bloomfield, Michigan

  • Washington University School of Medicine

    St Louis, Missouri

  • Impact Clinical Trials Las Vegas

    Las Vegas, Nevada

  • JFK Medical Center

    Edison, New Jersey

  • Institute of Neurology & Neurosurgery at St. Barnabas

    Livingston, New Jersey

Showing 40 of 67 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.